Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2018

16.08.2018 | Melanoma

Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities

verfasst von: Hidde M. Kroon, MD, PhD, Wendy D. van der Bol, MD, Katherine T. Tonks, MBBS, FRACP, Angela M. Hong, MBBS, PhD, FRANZCR, George Hruby, MBChB, FRANZCR, John F. Thompson, MD, FRACS, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

When cervical lymph nodes are clinically positive for metastatic melanoma, surgeons may be hesitant to recommend a therapeutic complete lymph node dissection if the patient is elderly or has major comorbidities. A limited local node excision of the clinically positive nodes only, followed by adjuvant radiotherapy to the entire node field, may be an effective alternative in such patients.

Methods

All patients who had presented with a primary head and neck melanoma or an unknown primary site and had subsequently undergone limited local node excision and adjuvant radiotherapy for macroscopically involved cervical nodes between 1993 and 2010 at a tertiary referral center were selected for study.

Results

Twenty-eight patients were identified, with a median age of 78 years and a median of 2 major comorbidities. The 5-year regional control, disease-free survival, and overall survival rates were 69%, 44%, and 50%, respectively. At the time of data analysis, seven patients were alive without evidence of disease. Twenty-one patients had died: 11 of melanoma (4 with neck recurrence) and 10 of other causes (2 with neck recurrence).

Conclusions

Excision of clinically positive metastatic cervical lymph nodes followed by radiotherapy provides satisfactory regional disease control without risking serious morbidity or mortality in melanoma patients whose general condition is considered a contraindication for therapeutic complete lymph node dissection.
Literatur
1.
Zurück zum Zitat Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92.
2.
Zurück zum Zitat Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AMM. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009;20(Suppl 6):vi22–9.CrossRefPubMedPubMedCentral Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AMM. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009;20(Suppl 6):vi22–9.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Andersen PS, Chakera AH, Thamsborg AK, Kølle SF, Schmidt G, Klyver H, Drzewiecki KT. Recurrence and survival after neck dissections in cutaneous head and neck melanoma. Dan Med J. 2014;61:A4953.PubMed Andersen PS, Chakera AH, Thamsborg AK, Kølle SF, Schmidt G, Klyver H, Drzewiecki KT. Recurrence and survival after neck dissections in cutaneous head and neck melanoma. Dan Med J. 2014;61:A4953.PubMed
4.
Zurück zum Zitat Mack LA, McKinnon JG. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol. 2004;86:189–99.CrossRefPubMed Mack LA, McKinnon JG. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol. 2004;86:189–99.CrossRefPubMed
5.
Zurück zum Zitat Martin RC, Shannon KF, Quinn MJ, et al. The management of cervical lymph nodes in patients with cutaneous melanoma. Ann Surg Oncol. 2012;19:3926–32.CrossRefPubMed Martin RC, Shannon KF, Quinn MJ, et al. The management of cervical lymph nodes in patients with cutaneous melanoma. Ann Surg Oncol. 2012;19:3926–32.CrossRefPubMed
6.
Zurück zum Zitat O’Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck. 1997;19:589–94.CrossRefPubMed O’Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck. 1997;19:589–94.CrossRefPubMed
7.
Zurück zum Zitat Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node filed relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1049–60.CrossRefPubMed Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node filed relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1049–60.CrossRefPubMed
8.
Zurück zum Zitat Grotz TE, Puig CA, Perkins S, Ballman K, Hieken TJ. Management of regional lymph nodes in the elderly melanoma patient: patient selection, accuracy and prognostic implications. Eur J Surg Oncol. 2015;41:157–64.CrossRefPubMed Grotz TE, Puig CA, Perkins S, Ballman K, Hieken TJ. Management of regional lymph nodes in the elderly melanoma patient: patient selection, accuracy and prognostic implications. Eur J Surg Oncol. 2015;41:157–64.CrossRefPubMed
9.
Zurück zum Zitat Geltzeiler M, Monroe M, Givi B, Vetto J, Andersen P, Gross N. Regional control of head and neck melanoma with selective neck dissection. JAMA Otolaryngol Head Neck Surg. 2014;140:1014–8.CrossRefPubMed Geltzeiler M, Monroe M, Givi B, Vetto J, Andersen P, Gross N. Regional control of head and neck melanoma with selective neck dissection. JAMA Otolaryngol Head Neck Surg. 2014;140:1014–8.CrossRefPubMed
10.
Zurück zum Zitat Balch CM, Soong SJ, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20:3961–8.CrossRefPubMedPubMedCentral Balch CM, Soong SJ, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20:3961–8.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Supriya M, Narasimhan V, Henderson MA, Sizeland A. Managing regional metastasis in patients with cutaneous head and neck melanoma is selective neck dissection appropriate? Am J Otolaryngol. 2014;35:610–6.CrossRefPubMed Supriya M, Narasimhan V, Henderson MA, Sizeland A. Managing regional metastasis in patients with cutaneous head and neck melanoma is selective neck dissection appropriate? Am J Otolaryngol. 2014;35:610–6.CrossRefPubMed
12.
Zurück zum Zitat O’Brien CJ, Petersen-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck. 1995;17:232–41.CrossRefPubMed O’Brien CJ, Petersen-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck. 1995;17:232–41.CrossRefPubMed
13.
Zurück zum Zitat Hamming-Vrieze O, Balm AJ, Heemsbergen WD, Hooft van Huysduynen T, Rasch CR. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. Arch Otolaryngol Head Neck Surg. 2009;135:795–800.CrossRefPubMed Hamming-Vrieze O, Balm AJ, Heemsbergen WD, Hooft van Huysduynen T, Rasch CR. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. Arch Otolaryngol Head Neck Surg. 2009;135:795–800.CrossRefPubMed
14.
Zurück zum Zitat Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50–60.CrossRef Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50–60.CrossRef
15.
Zurück zum Zitat Kaplan L, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1985;53:457–81.CrossRef Kaplan L, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1985;53:457–81.CrossRef
16.
Zurück zum Zitat Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed
17.
Zurück zum Zitat Oxenberg J, Kane JM III. The role of radiation therapy in melanoma. Surg Clin North Am. 2014;94:1031–47.CrossRefPubMed Oxenberg J, Kane JM III. The role of radiation therapy in melanoma. Surg Clin North Am. 2014;94:1031–47.CrossRefPubMed
18.
Zurück zum Zitat Van Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol. 2007;33:102–8.CrossRefPubMed Van Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol. 2007;33:102–8.CrossRefPubMed
19.
Zurück zum Zitat Feng Z, Gao Y, Niu LX, Peng X, Guo CB. Selective versus comprehensive neck dissection in the treatment of patients with a pathologically node-positive neck with or without microscopic extracapsular spread in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2014;43:1182–8.CrossRefPubMed Feng Z, Gao Y, Niu LX, Peng X, Guo CB. Selective versus comprehensive neck dissection in the treatment of patients with a pathologically node-positive neck with or without microscopic extracapsular spread in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2014;43:1182–8.CrossRefPubMed
20.
Zurück zum Zitat Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005;27:718–21.CrossRefPubMed Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005;27:718–21.CrossRefPubMed
21.
Zurück zum Zitat Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol. 2014;15:e371–81.CrossRefPubMed Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol. 2014;15:e371–81.CrossRefPubMed
22.
Zurück zum Zitat Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentral Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.CrossRefPubMed Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.CrossRefPubMed
24.
Zurück zum Zitat Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.CrossRefPubMedPubMedCentral Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.CrossRefPubMed Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.CrossRefPubMed
26.
Zurück zum Zitat Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.CrossRefPubMed Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.CrossRefPubMed
27.
Zurück zum Zitat Grünhagen DJ, Kroon HM, Verhoef C. Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy. Am Soc Clin Oncol Educ Book. 2015;35:e528–34.CrossRef Grünhagen DJ, Kroon HM, Verhoef C. Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy. Am Soc Clin Oncol Educ Book. 2015;35:e528–34.CrossRef
Metadaten
Titel
Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities
verfasst von
Hidde M. Kroon, MD, PhD
Wendy D. van der Bol, MD
Katherine T. Tonks, MBBS, FRACP
Angela M. Hong, MBBS, PhD, FRANZCR
George Hruby, MBChB, FRANZCR
John F. Thompson, MD, FRACS, FACS
Publikationsdatum
16.08.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6692-2

Weitere Artikel der Ausgabe 12/2018

Annals of Surgical Oncology 12/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.